SynDevRx, Inc.
SynDevRx is a pioneering biotechnology company focused on developing treatments for obesity-accelerated cancers through the emerging field of metabo-oncology. Their lead drug candidate, evexomostat (SDX-7320), targets the metabolic enzyme MetAP2 to treat various cancers, including prostate, breast, and pancreatic cancers, especially in patients with metabolic dysfunction such as obesity and diabetes. The company aims to improve cancer treatment outcomes by addressing the metabolic factors that contribute to cancer progression and resistance.
Industries
Nr. of Employees
small (1-50)
SynDevRx, Inc.
Patents
Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof
US-10722532-B2
View Details
Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof
US-10722532-B2
View DetailsProducts
Evexomostat (SDX-7320)
A polymer-conjugated methionine aminopeptidase type 2 (MetAP2) inhibitor developed as an anti-tumor and anti-metastatic agent with reported anti-angiogenic and anti-metabolic effects; being evaluated in combination regimens in early clinical trials.
Evexomostat (SDX-7320)
A polymer-conjugated methionine aminopeptidase type 2 (MetAP2) inhibitor developed as an anti-tumor and anti-metastatic agent with reported anti-angiogenic and anti-metabolic effects; being evaluated in combination regimens in early clinical trials.
Services
Design and execution support for early- and mid-stage oncology trials, including medical monitoring, safety oversight and outsourced CRO coordination.
Conduct of mechanistic studies, in vivo efficacy testing in PDX and obesity-driven models, and collaborative research funded by grants to support translational programs.
API process R&D, formulation development and clinical trial manufacturing support to enable early-phase studies.
Design and implementation of data warehouses and advanced analytics for bioinformatics and clinical data mining.
Design and execution support for early- and mid-stage oncology trials, including medical monitoring, safety oversight and outsourced CRO coordination.
Conduct of mechanistic studies, in vivo efficacy testing in PDX and obesity-driven models, and collaborative research funded by grants to support translational programs.
API process R&D, formulation development and clinical trial manufacturing support to enable early-phase studies.
Design and implementation of data warehouses and advanced analytics for bioinformatics and clinical data mining.
Expertise Areas
- Clinical trial management
- Metabo-oncology research
- Polymer-drug conjugates and prodrug design
- Preclinical pharmacology and in vivo models
Key Technologies
- Polymer-drug conjugation
- MetAP2 inhibition
- Patient-derived xenografts (PDX)
- Diet-induced obesity (DIO) tumor models
News & Updates
A phase 1 safety study of evexomostat in patients with late-stage cancer.
Research data on evexomostat (SDX-7320) showing potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant.
Participation in a podcast discussing metabo-oncology and breast cancer.
Presentation of scientific data on evexomostat demonstrating potent anti-fibrosis activity.
A podcast discussing breast cancer and metabolic health, featuring interviews with medical professionals.
A clinical trial testing evexomostat in combination with standard treatment for breast cancer patients with metabolic dysfunction.
A phase 1 safety study of evexomostat in patients with late-stage cancer.
Research data on evexomostat (SDX-7320) showing potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant.
Participation in a podcast discussing metabo-oncology and breast cancer.
Presentation of scientific data on evexomostat demonstrating potent anti-fibrosis activity.
A podcast discussing breast cancer and metabolic health, featuring interviews with medical professionals.
A clinical trial testing evexomostat in combination with standard treatment for breast cancer patients with metabolic dysfunction.